Clonazolam

DEA's final rule, effective April 1, 2026, permanently placed clonazolam in Schedule I. It supersedes the prior temporary Schedule I placement and extension through July 26, 2026.

Controlled under § 1, d), 2. of Nařízení vlády č. 463/2013 Sb. Use is restricted exclusively to limited research purposes or very limited therapeutic applications.

The current official order expressly lists exact clonazolam on list E. List E substances may only be used for medical and scientific purposes; receipt and possession are allowed only for the specified lawful recipients/cases in § 6.

The official Order expressly identifies Clonazolam by its full chemical name and declares every substance in its Schedule a controlled drug for purposes of the Misuse of Drugs Act 1977. The Schedule also covers stereoisomers, esters/ethers, salts, and preparations containing scheduled substances.

The official decree expressly adds exact clonazolam to Table IV of DPR 309/1990 (not Table I); it entered into force 15 days after publication. The Ministry states that Tables I–IV are nationally/internationally controlled substances and are updated as needed.

Clonazolam is expressly listed as a psychotropic, not a narcotic. The MHLW's 8 September 2021 notice identifies CLONAZOLAM among the three substances newly designated as psychotropics, effective 8 October 2021; handling is regulated under the Narcotics and Psychotropics Control Act.

Controlled as a List 2 substance under the Opium Law. Possession, production, and distribution are illegal.

Dangerous Drugs Board Regulation No. 6, series of 2022, includes clonazolam in the list of dangerous drugs. The underlying statute treats unauthorized importation, sale, and possession of dangerous drugs as unlawful, and clonazolam is controlled by name.

Clonazolam (Клоназолам) is expressly listed in List I of the current controlled-substances schedules established by Resolution No. 681. List I placement is prohibitory; it is not Schedule/List III.

Sweden expressly lists clonazolam under the Swedish name klonazolam and its exact chemical name, 6-(2-klorofenyl)-1-metyl-8-nitro-4H-[1,2,4]triazolo[4,3-a][1,4]bensodiazepin. It entered the national narcotics annex on August 18, 2015 under SFS 2015:526 and remains listed in Förordning (1992:1554), current through SFS 2026:1109. Läkemedelsverket's LVFS 2011:10 consolidation, current through HSLF-FS 2026:26, assigns it to Swedish list I (substances that normally have no medical use) and international list P IV. Import/export, manufacture, trade and possession are restricted to the purposes and authorized persons specified in Lag (1992:860). It is not currently governed as a good dangerous to health: Lag (1999:42) section 2(1) excludes narcotics from that regime. Folkhälsomyndigheten's historical recommendation sought narcotics classification, not a hazardous-goods listing.

Classified as a Class C drug under the May 2017 amendment to the Misuse of Drugs Act 1971, alongside several other designer benzodiazepines. Possession, production, and supply are criminal offenses.

The ODC entry for clonazolam requires an import licence and permit and an export licence and permit. These are Commonwealth import/export controls only and do not govern domestic possession, supply, manufacture, or use nationwide.

The current consolidated PV expressly names Clonazolam in Anlage 1 Z 2. The PV defines annexed substances as psychotropic substances and subjects their manufacture, processing, conversion, acquisition and possession to ministerial authorization, subject to specified exceptions.

Clonazolam is expressly named (not inferred from clonazepam or a class rule) in Lista B1. The current official ANVISA controlled-substances page identifies the list as the updated annex to Portaria 344/1998 and records RDC 581/2021's inclusion of Clonazolam in B1. Under Portaria 344/1998, substances in B1 are psychotropics subject to special control, including special authorization for listed-substance activities and prescription-notification requirements for dispensing medicines containing B1 substances.

Clonazolam is not expressly named in the current Schedule IV. On the supplied identity as a triazolobenzodiazepine, it falls within Schedule IV item 18's express benzodiazepine-and-derivatives class rule. CDSA ss. 5–7 prohibit Schedule-IV trafficking, import/export, and production except as authorized; simple possession is not prohibited by s. 4(1), which applies only to Schedules I–III.

Clonazolam is expressly listed in the current BtMG Anlage II (rather than merely covered by an analogue/group rule). Anlage II is the schedule of traffic-capable but non-prescribable narcotics. BtMG § 3(1) requires BfArM permission for manufacture, trade, import, export, supply, sale/other placing on the market, and acquisition. BtMG § 29(1) criminalizes unauthorized listed conduct and possession without written acquisition permission (up to five years' imprisonment or a fine, subject to the statute's terms). The exact substance is subject to a controlled, permission-based Schedule II regime, not an unqualified prohibition.

Clonazolam is expressly listed by name rather than controlled as an analogue. IV-P substances may be used only for medical, industrial, or research purposes (Act art. 33(1)); possession is limited to persons authorized under the Act (art. 34(1)). Manufacture, processing, alteration, import, distribution, wholesale trade, and cross-border movements are subject to the Act's authorizations/permits (arts. 35, 37, 40); unauthorized possession and specified unauthorized conduct carry criminal penalties (arts. 53, 55, 56, 62).

Portugal's official gazette expressly adds clonazolam, identified as 6-(2-Clorofenil)-1-metil-8-nitro-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepina, to Tabela IV of Decreto-Lei n.º 15/93.

Clonazolam is not named in the current First Schedule, and the Schedule's listed Class C benzodiazepines (nimetazepam, flunitrazepam and triazolam) do not create a general benzodiazepine-derivative rule. However, clonazolam's CNS-depressant activity brings it within the Act's functional definition of a psychoactive substance; absent an Act authorisation, manufacture, trafficking, import/export, possession and consumption are offences. The Act provides a defence for specified conduct undertaken for a legitimate purpose other than human consumption.

Clonazolam is expressly listed as a psychotropic drug in Appendix 6, the schedule for Article 2(3)(d) substances. Handling is prohibited for persons who are not authorized narcotics handlers, subject to statutory exceptions.

Clonazolam is expressly named, with its chemical designation, in List IV of Annex 1. Spain's current consolidated Real Decreto 2829/1977 subjects List IV substances to controlled manufacture, trade, import/export, and pharmacy dispensing; pharmacy dispensing of a substance itself is only on a magistral-formula prescription, while preparations containing it require a medical prescription. The order also states that no medicines containing these newly listed substances were authorized in Spain at the time of enactment.

The BetmVV-EDI consolidation applicable from 13 March 2026 expressly lists clonazolam in Annex 3, Verzeichnis b; AS 2023 5 inserted that exact entry effective 1 March 2023. Verzeichnis b contains controlled substances partially exempt from control measures, whereas Verzeichnis e is the separate Annex 6 category for materials and products suspected of narcotic-like effects. BetmKV Article 11(1) sets an operating-licence baseline for specified commercial and supply activities, subject to Article 4's homeopathic and analytical qualifications; under Article 11(3), medical professionals need no additional operating licence beyond their professional-practice authorization. Articles 46(3) and 48 provide a simple-prescription route and quantity rule for a medicine containing a Verzeichnis-b substance, but those provisions do not establish that a clonazolam medicine is authorized. BetmG applies its narcotics provisions to psychotropic substances unless otherwise provided. Article 19 penalizes unauthorized possession and acquisition, while Article 19a treats intentional unauthorized consumption and own-consumption conduct under Article 19 as punishable by a fine and permits dismissal, waiver of punishment, or a warning in minor cases. Article 19b narrowly makes preparation of only a minor quantity for one's own consumption, or its free provision to a person over 18 for simultaneous joint consumption, non-punishable. Licensing requirements differ by controlled act, and possession and personal-use conduct do not all receive the same treatment.